Pictured: Nancy Lee
In the Clinic
By Eva Kiesler, PhD, Science Writer/Editor  |  Monday, December 19, 2011

People with cancer of the nasopharynx, an area behind the nose, may benefit from a new combination therapy, according to an international study led by Memorial Sloan Kettering radiation oncologist Nancy Y. Lee.

Feature
By Eva Kiesler, PhD, Science Writer/Editor  |  Thursday, December 15, 2011

Memorial Sloan Kettering scientists, physicians, and administrators are developing and commercializing research discoveries to generate more-effective and affordable cancer treatments.

Honor
By Media Staff  |  Wednesday, December 14, 2011

Five Memorial Sloan Kettering scientists have been appointed to a new research team dedicated to identifying targets for therapies to treat a certain form of melanoma.

Pictured: Structural formula of IBNtxA
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Tuesday, December 13, 2011

Scientists have generated a compound that could potentially be used to create a new type of pain medication that may prevent the side effects of currently available painkillers.

In the Lab
By Julie Grisham, MS, Science Writer/Editor  |  Monday, December 12, 2011

A Memorial Sloan Kettering study suggests that a new, experimental treatment could make bone marrow and stem cell transplantation safer and more effective.

Pictured: Lloyd J. Old
In Memoriam
By Memorial Sloan Kettering  |  Sunday, December 4, 2011

Memorial Sloan Kettering notes with sadness the death of Lloyd J. Old, who was internationally recognized as one of the founders and standard bearers of the field of tumor immunology.

Research
Pictured: Breast tumor treated with paclitaxel
In the Lab
By Eva Kiesler, PhD, Science Writer/Editor  |  Friday, December 2, 2011

Recent findings by Memorial Sloan Kettering investigators suggest it might be possible to improve the effectiveness of chemotherapy for breast cancer by combining the treatment with a new type of drug called a cathepsin inhibitor.

Pictured: David Solit
In the Lab
By Media Staff  |  Wednesday, November 23, 2011

Research led by investigators at Memorial Sloan Kettering has identified a previously unknown mechanism of resistance to the newly approved melanoma drug vemurafenib.

Pictured: Evelyn Lauder
In Memoriam
By Memorial Sloan Kettering  |  Monday, November 14, 2011

Memorial Sloan Kettering mourns the loss of Evelyn H. Lauder, who was a tireless cancer research advocate and a member of our Board of Overseers.

Center News

Stay Informed

Get the latest information about cancer care and research every month.